The eye health company Bausch + Lomb announced on Monday that it is recalling several of its intraocular lenses due to safety concerns. The company said it was recalling several of its enVista ...

Bausch + Lomb has recalled lenses used during cataract surgery due to complications when the lenses are used, according to an announcement from the Canada-based eyecare company posted on the U.S ...

Eye health company Bausch & Lomb is recalling some of its intraocular lenses over possible safety concerns. The voluntary recall comes after the company “received reports of complications ...

March 27 (Reuters) - Bausch + Lomb (BLCO.TO), opens new tab said on Thursday it will recall some of its implantable eye lenses after receiving reports of complications, the cause of which could ...

Shares of eyecare company Bausch + Lomb (NYSE:BLCO) fell 10.6% in the afternoon session after the company announced the voluntary recall of intraocular lenses on its enVista platform. The recall ...

Please provide your email address to receive an email when new articles are posted on . Bausch + Lomb conducted an investigation and identified the cause and affected lots of the IOLs. Full market ...

Please provide your email address to receive an email when new articles are posted on . Bausch + Lomb has received reports of toxic anterior segment syndrome in patients with enVista IOLs.

Bausch + Lomb shares tumbled in intraday trading Friday, a day after the eye-care company announced a "voluntary recall" of some of its intraocular lenses due to safety concerns. On Thursday ...

Shares of eyecare company Bausch + Lomb (NYSE:BLCO) fell 21.2% in the morning session after the company reported weak first quarter 2025 results: constant currency revenue fell short of Wall ...

Eyecare company Bausch + Lomb (NYSE:BLCO) will be reporting earnings tomorrow before market open. Here’s what you need to know. Bausch + Lomb beat analysts’ revenue expectations by 1.8% last ...

For the last reported quarter, it was expected that Bausch + Lomb would post earnings of $0.24 per share when it actually produced earnings of $0.25, delivering a surprise of +4.17%.

Fitch Ratings upgraded its credit grade on both Bausch + Lomb Corp. and its parent company Bausch Health Cos., but said the eye care unit’s ratings will continue to be under pressure unless the ...